Analog Devices (ADI) Offering Possible 12.99% Return Over the Next 29 Calendar Days

Analog Devices's most recent trend suggests a bullish bias. One trading opportunity on Analog Devices is a Bull Put Spread using a strike $115.00 short put and a strike $105.00 long put offers a potential 12.99% return on risk over the next 29 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $115.00 by expiration. The full premium credit of $1.15 would be kept by the premium seller. The risk of $8.85 would be incurred if the stock dropped below the $105.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Analog Devices is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Analog Devices is bullish.

The RSI indicator is at 60.81 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Analog Devices

New Strong Sell Stocks for December 17th
Tue, 17 Dec 2019 15:43:33 +0000
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today

Hedge Funds Prefer Analog Devices Over ABB Ltd (ABB)
Fri, 13 Dec 2019 15:14:34 +0000
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

Large Option Traders Dumping Apple Puts Ahead Of Tariff Deadline
Tue, 10 Dec 2019 19:03:35 +0000
Apple, Inc. (NASDAQ: AAPL) has been one of the hottest stocks in the market in 2019, gaining 70.8% and reaching a $1.2 trillion market cap. On Tuesday, Benzinga Pro subscribers received 34 option alerts related to unusually large trades of Apple options. At 9:11 a.m., a trader sold 2,792 Apple put options with a $240 strike price expiring on Feb. 21 near the bid price at $3.551.

2 Stocks to Buy to Play Growth of 5G Phones, According to an Analyst
Mon, 09 Dec 2019 18:39:00 +0000
With 5G wireless mobile phones on the way, the time has come to buy shares of the key radio component vendors, according to BofA Global Research.

RBC: 3 “Strong Buy” Stocks That Could Step on the Gas in 2020
Fri, 06 Dec 2019 18:13:25 +0000
The Cambridge Dictionary’s definition of an expert is a “person with a high level of knowledge or skill relating to a particular subject or activity.”Apply this to the investing world, and how do we see this in action? We pull out TipRanks’ Top Wall Street Firms and notice who sits at the top of the heap.Occupying the throne right now is renowned investment bank RBC Capital, which means that among the company’s employees there are seasoned pros with a proven track record for success. Utilizing the TipRanks Stock Screener tool, we’ve found three stocks receiving Strong Buy ratings from most analysts in general, and endorsed by RBC in particular. Let’s take a closer look: Ovid Therapeutics (OVID)Ovid Therapeutics shares are on a tear. The stock price of this neurological medicines firm has raced ahead 66% this year, leaving the Nasdaq Biotechnology ETF (IBB) in its dust. But would you believe it has even further to run? Would you believe it could go up another 200%? RBC analyst Brian Abrahams does. In his latest research note, Abrahams reiterated an Outperform rating on OVID, along with a price target of $12.00 (To watch Abraham’s track record, click here)The drug maker has several therapies in the pipeline. Leading programs in development right now are OV101, which focuses on a potential treatment for Angelman syndrome and Fragile X syndrome, two neurodevelopmental disorders caused by genetic mutations, and OV935, a program focused on developing potential therapies for people living with rare epilepsies.Top-line data from a Phase 3 NEPTUNE trial of OV101 in Angelman's Syndrome should be released in mid-2020, and Abrahams thinks there is a very reasonable chance of success. While acknowledging some risk given disease heterogeneity, unclear dose dependence, and inconsistent subdomain effects in ph.II, the 5-star analyst noted, “We believe clinical and preclinical data for the company's lead candidate OV101, an extrasynaptic GABAA receptor agonist, are in totality supportive of the drug's activity in Angelman Syndrome, and believe the stock price currently underappreciates the likelihood the drug succeeds in improving clinical symptoms of the disease in ph.III. Given the high unmet need in this population, we believe FDA will be permissive — highlighted by the Agency's endorsement of the pivotal trial design — and if approved, should enable good uptake and pricing power.”Other analysts are even more optimistic. Indeed, the average price target on Wall Street is $13.50 — implying nearly 240% upside. And over the last three months, no one on the Street has assigned Ovid shares anything less than a "buy" rating. (See Ovid stock analysis on TipRanks)Anaplan (PLAN)This year has seen a number of car crash IPO’s, as several over valued startups got on the receiving end of a harsh reality check following public listings. One to avoid such a fate, is cloud computing ‘connected planning’ platform, Anaplan.The company’s name derives from the combination of analysis and planning, which makes sense to us, as it makes software that connects people in a shared environment to business data in order to make better-informed plans and decisions.Anaplan impressed Wall Street with its latest F3Q20 earnings report. The company handily beat expectations on several key metrics, including top-line, billings, and margins. Additionally, this led to management significantly boosting its FY20 guidance.RBC’s Alex Zukin believes that a ‘large addressable market’ can serve as a catalyst for Anaplan’s growth, noting, “Anaplan indicates that the Planning market is a $21B+ opportunity (based on IDC forecasts). We believe customers are paying legacy vendors billions of dollars today and there is potential for spend significantly above that if greenfield, excel-based business processes meaningfully start to convert to Planning vendors.”Anaplan’s growth potential has Zukin reiterating his Outperform rating, along with a price target of $70. PLAN is currently trading at $52.56, indicating gains of 33% might be in the cards should Zukin’s target materialize. (To watch Zukin’s track record, click here)What’s the Street’s plan for PLAN, then? The consensus is that the connected planning innovator is a Strong Buy, a rating achieved as a result of 9 "buy" and 3 "hold" ratings issued in the past 3 months. The average stock-price forecast of $63.33 implies upside potential of 20% from current levels. (See PLAN stock analysis on TipRanks)Analog Devices (ADI)Last and least, we come to semiconductor maker Analog Devices, which scored an "outperform" rating (i.e. "buy") from 5-star RBC analyst Mitch Steves.ADI stock is up nearly 38% in 2019 compared to the S&P 500, which has returned 24%. That’s impressive, but the big question for investors is whether the company (and its stock) can maintain the momentum. Steves suggests that if everything goes as planned, ADI will be a $136 stock in the next 12 months, implying about 18% return. (To watch Steves’ track record, click here)The company’s recent FQ4 numbers were mildly below Street expectations. Revenues of $1.44 billion slightly missed the Street’s estimate of $1.45 billion, while EPS of $1.19 came below the $1.22 estimate. FQ1 guidance also missed the Street’s targets.Steves commented, “We continue to believe that sentiment is still quite negative on the stock and remain positive as operating margin expansion should begin in Q2 and beyond […] We remain positive on ADI and its suggestion of a recovery in Q2 is in line with our Analog view as well.” The analyst further added, “We are seeing positive trends within ADI’s communications business, as the company manages to sustain share gain and capture 5G opportunities. Being exposed to 5G radio content represents significant differentiation relative to the analog group, in our view.”The RBC expert is not alone in his take on ADI, as 11 Buys and 3 Holds from the analysts tracked by TipRanks over the last 3 months result in a Strong Buy consensus rating. The average price target stands at $125.57. (See ADI stock analysis on TipRanks)

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.